Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) and Australian biotechnology company Audax Biosciences Pty Ltd announced on Tuesday that they have entered into an exclusive option and licence agreement for DAX-044, Audax's lead immuno-oncology AVIKINE candidate.
Under the agreement, Astellas receives an exclusive option for a worldwide licence to develop, manufacture and commercialise DAX-044. Audax has the option to co-fund and co-promote DAX-044 in Australia and New Zealand.
DAX-044 is an investigational, immune-targeted interleukin-12 (IL-12) antibody-cytokine fusion, designed with AVIKINE technology to concentrate IL-12's immune-activating activity within the tumour microenvironment while limiting the systemic toxicity that has historically constrained IL-12-based therapy. DAX-044 has demonstrated a potential best-in-class therapeutic index for an IL-12 agent in preclinical studies and is currently in IND/CTN-enabling development.
Under the terms of the agreement, Audax will receive upfront and potential future option exercise payment totalling USD285m and continue development of DAX-044 into a Phase 1 study expected to commence in 2027. On exercising its option, Astellas will assume sole responsibility for global development, manufacturing and commercialisation, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand. In addition, Audax will be eligible to receive development and commercial milestone payments of up to USD1.05bn, as well as tiered double-digit royalties on worldwide net sales of DAX-044, if approved.
Exercise of the option is subject to customary conditions, including antitrust clearance.
INOVIO prices public offering of approximately USD75m
First patient dosed in Phase 1 trial of Transgene and BioInvent's BT-001 for rectal cancer
Elicera Therapeutics secures Chinese patent allowance for ELC-401
CHOSA Oncology signs US laboratory agreement for Platin-DRP commercialisation
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
Pentixapharm advances preparationsfor Phase 3 PANDA study
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lytix Biopharma's ruxotemitide combination meets primary endpoint in Phase II melanoma trial
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Phrontline Biopharma reports preliminary safety and antitumour activity for TJ101
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Genmab reports 50% reduction in risk of death in Phase 3 head and neck cancer trial
Novocure and Verastem to evaluate combination therapy for pancreatic cancer